Fiche société
Boryung Pharmaceutical Co., Ltd
Traitements, essais et publications liés.
Traitements14programmes
Essais3liés
Publications3liées
SourceDBlocale
Traitements
14| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| BR1019The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers | Hypertension | Phase 1 | À vérifier | South Korea | À vérifier |
| BR1019-1The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers | Hypertension | Phase 1 | À vérifier | South Korea | À vérifier |
| BR1019-2The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers | Hypertension | Phase 1 | À vérifier | South Korea | À vérifier |
| BR1019AThe objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| BR1019A-1The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| BR1019BThe objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| BR1019B-1The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| BR1019CThe objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| BR1019C-1The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
| Fimasartan + AmlodipineThe purpose of this study is to evaluate the pharmacokinetics and safety when administrated Fimasartan/Amlodipine and when co-administrated Fimasartan and Amlodipine. | Hypertension | Phase 1 | À vérifier | À vérifier | |
| Fimasartan/AmlodipineThe purpose of this study is to evaluate the pharmacokinetics and safety when administrated Fimasartan/Amlodipine and when co-administrated Fimasartan and Amlodipine. | Hypertension | Phase 1 | À vérifier | À vérifier | |
| BR1019The objective of this clinical study is to evaluate the pharmacokinetics and the safety after administration of "BR1019" and co-administration of "BR1019-1" and "BR1019-2" in healthy volunteers | Hypertension | Phase 1 | À vérifier | South Korea | À vérifier |
| Fimasartan/AmlodipineThe purpose of this study is to evaluate the pharmacokinetics and safety when administrated Fimasartan/Amlodipine and when co-administrated Fimasartan and Amlodipine. | Hypertension | Phase 1 | À vérifier | À vérifier | |
| BR1019AThe objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus | Hypertension | Phase 3 | À vérifier | Indonesia, South Korea | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| BR1019A | Hypertension | Phase 3 | NCT06220773 | A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy | RECRUITING |
| Fimasartan/Amlodipine | Hypertension | Phase 1 | NCT02920047 | A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects | COMPLETED |
| BR1019 | Hypertension | Phase 1 | NCT06226727 | A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1019" and Co-administration of "BR1019-1" and "BR1019-2" | COMPLETED |
Publications
3| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Fimasartan/Amlodipine | Pharmacokinetic comparison between a fixed-dose combination of fimasartan/amlodipine/hydrochlorothiazide 60/10/25 mg and a corresponding loose combination of fimasartan/amlodipine 60/25 mg and hydrochlorothiazide 25 mg in healthy subjects. | Translational and clinical pharmacology | ||
| Fimasartan/Amlodipine | Simultaneous Analysis of a Combination of Anti-Hypertensive Drugs, Fimasartan, Amlodipine, and Hydrochlorothiazide, in Rats Using LC-MS/MS and Subsequent Application to Pharmacokinetic Drug Interaction with Red Ginseng Extract. | Toxics | ||
| Fimasartan/Amlodipine | A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy. | Clinical hypertension |